PI-620
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 12, 2022
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
(clinicaltrials.gov)
- P1; N=15; Recruiting; Sponsor: Life Molecular Imaging GmbH
Clinical • New P1 trial • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • MRI
October 25, 2021
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
(clinicaltrials.gov)
- P1; N=10; Recruiting; Sponsor: Life Molecular Imaging GmbH; Trial completion date: Aug 2021 ➔ Jun 2022; Trial primary completion date: Jun 2021 ➔ Jun 2022
Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy • MRI • Tau PET
January 20, 2021
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
(clinicaltrials.gov)
- P1; N=10; Recruiting; Sponsor: Life Molecular Imaging GmbH
Clinical • New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy
1 to 3
Of
3
Go to page
1